Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Arcus Biosciences ( (RCUS) ) is now available.
On October 12, 2025, Arcus Biosciences announced the first overall survival results from the Phase 2 EDGE-Gastric study, showing promising efficacy of the domvanalimab plus zimberelimab and chemotherapy regimen in patients with advanced gastric and esophageal cancers. The study, which evaluated 41 patients, demonstrated sustained efficacy across all PD-L1 subgroups with a median overall survival of 26.7 months and a favorable safety profile, indicating potential advancements in cancer treatment options.
The most recent analyst rating on (RCUS) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
Spark’s Take on RCUS Stock
According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.
The overall stock score is primarily influenced by strong technical momentum, which is a positive indicator for short-term performance. However, financial performance challenges, particularly in profitability and cash flow, weigh heavily on the score. The negative valuation metrics further underscore the need for improved financial health to support long-term growth.
To see Spark’s full report on RCUS stock, click here.
More about Arcus Biosciences
Arcus Biosciences, Inc. operates in the biotechnology industry, focusing on the development of cancer therapies. The company is known for its efforts in creating innovative treatments for various types of cancer, including gastric and esophageal adenocarcinoma.
Average Trading Volume: 860,182
Technical Sentiment Signal: Buy
Current Market Cap: $1.55B
Learn more about RCUS stock on TipRanks’ Stock Analysis page.